Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar User Fee Negotiations Under Way; Timetable Compressed

Executive Summary

FDA has started biosimilar user fee negotiations with industry, although it does not appear the room is overcrowded with participants.
Advertisement

Related Content

Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
FDA Emergency Use Power Could Expand Under Bill Moving To House Floor
FDA Emergency Use Power Could Expand Under Bill Moving To House Floor
Reactivation Fee Is Proposed For Biosimilar INDs Placed On Hold
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Biosimilar User Fees Would Be Same As BLAs, Only Earlier
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle
PDUFA V: FDA Application Completeness Crackdown Continues

Topics

Advertisement
UsernamePublicRestriction

Register

PS053548

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel